lestaurtinib has been researched along with Cancer of Lung in 3 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 3 (100.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Aiche, S; Bassermann, F; Becker, W; Canevari, G; Casale, E; Depaolini, SR; Ehrlich, HC; Felder, ER; Feuchtinger, A; Garz, AK; Gohlke, BO; Götze, K; Greif, PA; Hahne, H; Heinzlmeir, S; Helm, D; Huenges, J; Jeremias, I; Kayser, G; Klaeger, S; Koch, H; Koenig, PA; Kramer, K; Kuster, B; Médard, G; Meng, C; Petzoldt, S; Polzer, H; Preissner, R; Qiao, H; Reinecke, M; Reiter, K; Rueckert, L; Ruland, J; Ruprecht, B; Schlegl, J; Schmidt, T; Schneider, S; Schoof, M; Spiekermann, K; Tõnisson, N; Vick, B; Vooder, T; Walch, A; Wilhelm, M; Wu, Z; Zecha, J; Zolg, DP | 1 |
| Cobb, MH; Girard, L; Gonzales, JX; Kulkarni, A; Larsen, JE; Minna, JD; Osborne, JK; Sato, M; Shames, DS; Shields, MD; Wistuba, II | 1 |
| Li, JS; Wang, XW; Wang, YW; Zhang, HY | 1 |
3 other study(ies) available for lestaurtinib and Cancer of Lung
| Article | Year |
|---|---|
The target landscape of clinical kinase drugs.
Topics: Animals; Antineoplastic Agents; Cell Line, Tumor; Cytokines; Drug Discovery; fms-Like Tyrosine Kinase 3; Humans; Leukemia, Myeloid, Acute; Lung Neoplasms; Mice; Molecular Targeted Therapy; Protein Kinase Inhibitors; Protein Serine-Threonine Kinases; Proteomics; Xenograft Model Antitumor Assays | 2017 |
NeuroD1 regulates survival and migration of neuroendocrine lung carcinomas via signaling molecules TrkB and NCAM.
Topics: Analysis of Variance; Animals; Basic Helix-Loop-Helix Transcription Factors; Carbazoles; Cell Line, Tumor; Cell Movement; Cell Survival; Chromatin Immunoprecipitation; DNA Primers; Furans; Humans; Immunoblotting; Immunoprecipitation; Luciferases; Lung Neoplasms; Mice; Microarray Analysis; Neural Cell Adhesion Molecules; Plasmids; Real-Time Polymerase Chain Reaction; Receptor, trkB; Small Cell Lung Carcinoma | 2013 |
Integrated Exploitation of the Structural Diversity Space of Chemotherapy Drugs to Selectively Inhibit HER2 T798M Mutant in Lung Cancer.
Topics: Binding Sites; Carbazoles; Catalytic Domain; Furans; Humans; Kinetics; Ligands; Lung Neoplasms; Molecular Docking Simulation; Mutation; Protein Binding; Protein Kinase Inhibitors; Receptor, ErbB-2; Staurosporine; Thermodynamics | 2017 |